 |
인쇄하기
취소
|
Phase II study on SK-3530 impotence drug successfully completed.
SK Chemical's joint phase II study on SK-3530, an impotence drug, with Intogene Inc. (CEO : Kim Dae-gi) seems to be successfully completed according to their announcement on April 26.
The study was performed by 10 general hospitals including Seoul National Univ. hospital starting from Sept. last year in compliance to the IIEF (International Index of Erectile Function) standards, SEP 2 (an i...
The study was performed by 10 general hospitals including Seoul National Univ. hospital starting from Sept. last year in compliance to the IIEF (International Index of Erectile Function) standards, SEP 2 (an i...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.